Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial
详细信息 查看全文
- 作者：Alexander Meisela ; b ; Stefanie von Feltenc ; 1 ; Deborah R. Vogtc ; 1 ; Heike Lieweng ; Ronald de Witd ; Johann de Bonoe ; Oliver Sartorf ; Frank Stenner-Lieweng ;
- 关键词：TROPIC ; Post hoc analysis ; Cabazitaxel chemotherapy ; Metastasized castration resistent prostate cancer ; Neutropenia predictive ; Granulocyte-colony stimulating factor (GCSF) ; mCRPC
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：56
- 期：Complete
- 页码：93-100
- 全文大小：748 K
文摘
- •
Cabazitaxel is an option in metastasized castration resistant prostate cancer (mCRPC).
- •
The occurrence of cabazitaxel induced neutropenia (CIN) is a positive predictive factor.
- •
Severe CIN is associated with better progression-free and overall survival.
- •
Prophylactic use of filgrastim (G-CSF) after first CIN shows a survival advantage.
- •
A model of neutrophil-to-lymphocyte ratio and CIN defines three risk categories in mCRPC.